Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Chief Accounting Officer | December 04, 2020 | December 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date December 04, 2020 · Filed December 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 93,041 |
Ending reported balance
After 2020-12-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-04 · Exercise / conversion · Acquired 5,639 · Balance 98,680 Row 2 · 2020-12-04 · Sale · Disposed 5,639 · Balance 93,041 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2020-12-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-04 · Exercise / conversion · Disposed 5,639 · Balance 0 F2: This option, granted as an annual performance award, is presently exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option, granted as an annual performance award, is presently exercisable in full.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DYNAVAX TECHNOLOGIES CORP
Report date February 10, 2026 · Filed February 10, 2026
Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Other · Disposed 60,204 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price. |
| Common Stock - Performance Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-10 transaction · row 5
4 source rows · reconciled sequenceRow 2 · 2026-02-10 · Grant · Acquired 46,430 · Balance 46,430 F4: Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2026. Row 3 · 2026-02-10 · Disposition to issuer · Disposed 46,430 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Row 4 · 2026-02-10 · Grant · Acquired 42,424 · Balance 42,424 F6: Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027. Row 5 · 2026-02-10 · Disposition to issuer · Disposed 42,424 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.90 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-10 · Disposition to issuer · Disposed 350,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.74 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-10 · Disposition to issuer · Disposed 90,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-10 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.48 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-10 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.69 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-10 · Disposition to issuer · Disposed 70,000 · Balance 0 F8: The stock option was granted to the Reporting Person in 2025. F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-10 · Disposition to issuer · Disposed 15,476 · Balance 0 F9: The restricted stock units ("RSUs") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024. F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F10: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-10 · Disposition to issuer · Disposed 28,283 · Balance 0 F11: The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025. F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F10: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price.
F4: Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2026.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
F6: Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027.
F7: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
F8: The stock option was granted to the Reporting Person in 2025.
F9: The restricted stock units ("RSUs") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024.
F10: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement.
F11: The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerRestricted Stock Units · Derivative | 28,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 12 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,283 shares Expires not disclosed F11 · derivative.exercise_price: The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025. F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F10 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F10 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F10 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerRestricted Stock Units · Derivative | 15,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 11 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,476 shares Expires not disclosed F9 · derivative.exercise_price: The restricted stock units ("RSUs") were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024. F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F10 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F10 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F10 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any portion of an RSU award granted in calendar year 2025 that remained unvested as of immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $12.69 | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 10 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires not disclosed F8 · security: The stock option was granted to the Reporting Person in 2025. F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $12.48 | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 9 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $11.12 | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 8 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,500 | Not disclosed Strike: $12.74 | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 7 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerStock Option (Right to Buy) · Derivative | 350,000 | Not disclosed Strike: $8.90 | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · derivative · entry 6 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F7 · price: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time (other than a stock option granted in calendar year 2025 became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option, except that in the case of any portion of a stock option granted in calendar year 2025 that remained unvested as of the immediately prior to the Effective Time, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerCommon Stock - Performance Stock Units | 42,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · nonDerivative · entry 5 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock - Performance Stock Units | 42,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · nonDerivative · entry 4 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,424 F6 · price: Represents PSUs previously granted to the Reporting Person in 2025, which vest based on rTSR over a performance period ending on December 31, 2027. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Disposition to issuerCommon Stock - Performance Stock Units | 46,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · nonDerivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such PSU award immediately prior to the Effective Time based on attainment of the performance goal at 150% of the target level, without regard to vesting, multiplied by (ii) the Offer Price, except that in the case of any PSU award that was granted in calendar year 2025, 50% of such cash amount is subject to vesting requirements and scheduled to vest 6 months after the Effective Time, as described in the Merger Agreement. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock - Performance Stock Units | 46,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,430 F4 · price: Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person in 2024, which vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2026. Read SEC document |
| February 10, 2026 Filed Feb 10, 2026 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | OtherCommon Stock | 60,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781117-26-000002 · form4-02102026_040217.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 36,141 | $15.38 | $555,848.58 |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · nonDerivative · entry 4 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,204 F4 · shares: Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of PSUs and RSUs. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 14,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · derivative · entry 6 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,282 Underlying: Common Stock · 14,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the Reporting Person, effective as of the Effective Date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025. F6 · derivative.expiration_date: The RSUs were granted on February 13, 2025, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 13, 2025. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 15,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · derivative · entry 5 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,477 Underlying: Common Stock · 15,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1 · kind: On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the Reporting Person, effective as of the Effective Date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024. F5 · derivative.expiration_date: The RSUs were granted on February 15, 2024, and were originally scheduled to vest over three years, with 1/3 vesting on each anniversary of February 15, 2024. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 14,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · nonDerivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the Reporting Person, effective as of the Effective Date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 15,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the Reporting Person, effective as of the Effective Date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 16:15 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-058992 · wk-form4_1767042911.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,727 F1 · kind: On December 23, 2025 (the "Effective Date"), in connection with the execution of an Agreement and Plan of Merger dated as of the Effective Date (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, the Board of Directors of the Issuer approved acceleration of vesting of certain performance-based restricted stock units ("PSUs") and restricted stock units ("RSUs") previously granted to the Reporting Person, effective as of the Effective Date. F2 · price: Represents PSUs previously granted to the Reporting Person that vest based on how the Issuer's total stockholder return compares to the total stockholder return of an indexed group of companies ("rTSR") over a performance period ending on December 31, 2025. Each PSU represents a contingent right to receive one share of common stock. On the Effective Date, the Board of Directors of the Issuer determined that these PSUs (which represent 125% of the target number of PSUs) were earned according to achievement of the rTSR performance condition over a shortened performance period, with the Issuer's total stockholder return determined based on the amount payable for a share of the Issuer's common stock pursuant to the Merger Agreement ($15.50), and approved such acceleration of vesting of the earned PSUs. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 19:29 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 15,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000055 · wk-form4_1740097777.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,953 Underlying: Common Stock · 15,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 19:29 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 4,975 | $12.93 | $64,326.75 |
DisclosureSEC source: 0001029142-25-000055 · wk-form4_1740097777.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,227 F2 · shares: Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 19:29 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 15,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000055 · wk-form4_1740097777.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 42,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · derivative · entry 6 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,424 Underlying: Common Stock · 42,424 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025. F5 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 13, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $12.69 | Not disclosed |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · derivative · entry 5 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-13 F4 · price: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. F3 · derivative.exercise_date: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 13, 2025, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 16,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · derivative · entry 4 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · price: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 16,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · price: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 5,318 | $12.69 | $67,485.42 |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,725 F2 · shares: Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 17:10 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 16,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000035 · wk-form4_1739916608.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of common stock. These RSUs vested upon the Issuer's achievement of a certain performance condition. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:59 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000022 · wk-form4_1739397585.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:59 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 1,997 | $13.20 | $26,360.40 |
DisclosureSEC source: 0001029142-25-000022 · wk-form4_1739397585.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,043 F2 · shares: Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 16:59 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 5,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001029142-25-000022 · wk-form4_1739397585.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:44 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 46,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-003548 · doc4.xml · derivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,430 Underlying: Common Stock · 46,430 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F1 · kind: Code A: Grant, award or other acquisition F3 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:44 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Options (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001209191-24-003548 · doc4.xml · derivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-02-15 F1 · kind: Code A: Grant, award or other acquisition F2 · derivative.exercise_date: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 15, 2024, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 17:16 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 2,985 | $12.82 | $38,267.70 |
DisclosureSEC source: 0001209191-24-003196 · doc4.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,707 F3 · kind: Code F: Payment of exercise price or tax liability by delivering or withholding securities F4 · shares: Shares withheld by Dynavax Technologies Corporation to satisfy tax withholding requirements on vesting of restricted stock units. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 17:16 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-003196 · doc4.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · kind: Code M: Exercise or conversion of derivative security F2 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 17:16 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 5,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-003196 · doc4.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Code M: Exercise or conversion of derivative security F2 · shares: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 16:52 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionRestricted Stock Unit · Derivative | 5,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014170 · doc4.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,666 Underlying: Common Stock · 5,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 16:52 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Tax withholdingCommon Stock | 2,975 | $10.36 | $30,821.00 |
DisclosureSEC source: 0001209191-23-014170 · doc4.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,359 F2 · shares: The reporting person is reporting the withholding by Dynavax Technologies Corporation of 2,975 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of common stock to the reporting person on February 27, 2023. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 16:52 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | Exercise / conversionCommon Stock | 5,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014170 · doc4.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F1 · price: Each RSU represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 17:25 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $11.12 | Not disclosed |
DisclosureSEC source: 0001209191-23-011297 · doc4.xml · derivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-15 F1 · price: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. F1 · derivative.exercise_date: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 16, 2023, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:09 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantRestricted Stock Unit · Derivative | 16,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-009592 · doc4.xml · derivative · entry 2 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 10, 2022 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:09 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 90,500 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001209191-22-009592 · doc4.xml · derivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,500 Underlying: Common Stock · 90,500 shares Expires 2029-02-09 F1 · derivative.exercise_date: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 10, 2022, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 19:58 UTC | DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $8.90 | $0.00 |
DisclosureSEC source: 0001209191-21-016520 · doc4.xml · derivative · entry 1 MacDonald Kelly · CIK 0001781117 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-02-29 F1 · price: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of March 1, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. F1 · derivative.exercise_date: This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of March 1, 2021, and one thirty-sixth (1/36) of the shares subject to the option vesting each month thereafter. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,639 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0001209191-20-062229 · doc4.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,639 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 5,639 | $12.50 | $70,487.50 |
DisclosureSEC source: 0001209191-20-062229 · doc4.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,041 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 5,639 | $9.12 | $51,427.68 |
DisclosureSEC source: 0001209191-20-062229 · doc4.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,561 | $0.00 Strike: $9.31 | $0.00 |
DisclosureSEC source: 0001209191-20-058270 · doc4.xml · derivative · entry 3 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,561 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, granted as a promotion award, is presently exercisable in full. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,561 | $11.75 | $41,841.75 |
DisclosureSEC source: 0001209191-20-058270 · doc4.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,041 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 3,561 | $9.31 | $33,152.91 |
DisclosureSEC source: 0001209191-20-058270 · doc4.xml · nonDerivative · entry 1 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 100 | $10.92 | $1,092.00 |
DisclosureSEC source: 0001209191-20-057611 · doc4.xml · nonDerivative · entry 3 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,041 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 15, 2017. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 21:10 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 825 | $10.92 | $9,009.00 |
DisclosureSEC source: 0001209191-20-057611 · doc4.xml · nonDerivative · entry 2 MacDonald Kelly · CIK 0001781117 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,141 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on December 16, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.